VIDEO: Voclosporin seen as well tolerated in patients with lupus nephritis for 3 years
Click Here to Manage Email Alerts
ORLANDO — In this video from ASN Kidney Week, Samir V. Parikh, MD, discusses the results of the AURORA 2 study.
“The AURORA 1 study completed, and voclosporin, the study therapy in question, received its FDA label last year,” Parikh told Healio.
In AURORA 2, patients with lupus nephritis were blindly randomized to receive either voclosporin or placebo for 2 years. For some patients who continued treatment from AURORA 1, the total treatment time was 3 years.
Overall rates of serious adverse events were similar across groups, according to researchers, and there were no deaths in the voclosporin group.
Researchers identified good renal outcomes in 66.4% of patients in the voclosporin group compared with 54% of patients in the control group. Further, renal flares occurred in 23.8% of the patients in the voclosporin group and in 26% of patients in the control group.
“The highlight from this work was that voclosporin was largely well tolerated over this 3-year time period,” Parikh said.
Collapse
Parikh SV, et al. TH-PO486. Presented at: ASN Kidney Week; Nov. 3-6, 2022; Orlando (hybrid meeting).
Read more about
Click Here to Manage Email Alerts